Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ME2 | P23368 | 3/20 | 0.35 |
| ▸ | ME1 | P48163 | 3/20 | 0.35 |
| ▸ | ME3 | Q16798 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737224 | 0.90 | SIGMAR1 (0.40) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL735769 | 0.85 | HTR1A (0.46) | FASNLMNAGAASIGMAR1HTR7 | |
| SCHEMBL737729 | 0.84 | ME3 (0.37) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL735820 | 0.83 | SIGMAR1 (0.54) | MAPTLMNAGAASIGMAR1OPRM1 | |
| SCHEMBL735677 | 0.83 | SIGMAR1 (0.52) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL738524 | 0.82 | MAPT (0.38) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL737239 | 0.81 | SIGMAR1 (0.44) | MAPTKDM4ELMNASIGMAR1OPRM1 | |
| SCHEMBL736683 | 0.80 | MAPT (0.44) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL738435 | 0.79 | FASN (0.53) | FASNMAPTKDM4ELMNAGAA | |
| SCHEMBL11289188 | 0.78 | FASN (0.44) | FASNMAPTLMNASIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | FASN 4745/4885MAPT 4377/4885KDM4E 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.